There was no distal embolization requiring treatment. Overall bailout stenting rate was 17% (0 JET + DCB versus 50% PCB, P< 0.0001). Procedural success was superior with JET + PCB (87.1%) vs PTA + PCB alone (52.9% P=0.0147). There were no other differences in demographic or angiographic variables between the two groups. Results: Mean lesion length was 10.8± 4.3 cm for JET + PCB and 11.2± 7.6 cm for PTA + PCB (P=0.858). Analysis was performed on intention to treat. Freedom from target-lesion revascularization (TLR) was evaluated at 1 year. The In.PACT (Medtronic) and Ranger (Boston Scientific) PCBs were used. A total of 47 patients (48 lesions) with claudication (80.9%) or rest pain/ulcerations (19.2%) were randomly assigned 2:1 to JET + PCB (n=31) or PTA + PCB (n=16). The data are thus considered exploratory.

The study intended to enroll 255 patients, but was stopped early because of poor enrollment due to COVID-19 and concerns about the association of paclitaxel with mortality. Methods: The JET-RANGER study was a multicenter (eleven US centers) randomized trial, core lab–adjudicated, designed to demonstrate the superiority of JET + PCB versus PTA + PCB in treating FP arterial disease. Nicolas W Shammas, 1 Bhaskar Purushottam, 2 W John Shammas, 1 Lori Christensen, 1 Gail Shammas, 1 Desyree Weakley, 1 Sue Jones-Miller 1 On behalf of the JET-RANGER InvestigatorsġMidwest Cardiovascular Research Foundation, Davenport, IA, USA 2Regional Health CR, Cardiovascular Medicine, Monument Health, Rapid City, SD, USAĬorrespondence: Nicolas W Shammas, Research Director, Midwest Cardiovascular Research Foundation, 630 East 4th Street, Suite A, Davenport, IA, USA, Email īackground: It is unknown at this time whether Jetstream atherectomy (JET) and paclitaxel-coated balloon (PCB) provides a superior outcome to balloon angioplasty (PTA) followed by PCB in treating femoropopliteal (FP) arterial disease.

How to get back deleted emails mchsi